Vertex Newswire

Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 239 in Vertex

  1. Vertex Pharmaceuticals Upgraded at Vetr Inc.Read the original story

    22 hrs ago | AmericanBankingNews.com

    ... stock. Vetr 's price target would suggest a potential upside of 12.69% from the stock's previous close. Shares of Vertex Pharmaceuticals ( NASDAQ:VRTX ) traded down 4.87% during mid-day trading on Monday, reaching $127.52. 1,711,093 shares of the ...

    Comment?

  2. Vertex Pharmaceuticals Upgraded at Vetr Inc.Read the original story

    Saturday Aug 29 | AmericanBankingNews.com

    ... stock. Vetr 's price target suggests a potential upside of 6.36% from the company's previous close. Shares of Vertex Pharmaceuticals ( NASDAQ:VRTX ) traded up 0.22% during mid-day trading on Monday, hitting $134.05. 1,240,196 shares of the company ...

    Comment?

  3. Five things you should know about Kevin KinsellaRead the original story w/Photo

    Friday Aug 28 | Boston.com

    Kevin Kinsella is founder of the venture capital firm Avalon Ventures, which has offices in Cambridge and La Jolla, Calif. An MIT graduate, he is also founding chairman of Boston-based Vertex Pharmaceuticals and has helped finance and develop more than 100 other early-stage biotech and high-tech companies.

    Comment?

  4. Vertex Pharmaceuticals Director Sells $1,296,984.00 in StockRead the original story

    Friday Aug 28 | AmericanBankingNews.com

    Vertex Pharmaceuticals Director Joshua S. Boger sold 10,400 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $124.71, for a total value of $1,296,984.00.

    Comment?

  5. Meet the 2015 BBJ Innovation All-StarsRead the original story w/Photo

    Thursday Aug 27 | Business Journal

    ... capital, adding jobs, and transforming every area of technology and the life sciences. Joshua Boger, founder of Vertex Pharmaceuticals, will receive the BBJ's Innovation All-Stars Lifetime Achievement Award. In addition, 15 people are being ...

    Comment?

  6. 4 Biotechs Piper Jaffray Is Buying On The PullbackRead the original story w/Photo

    Wednesday Aug 26 | Benzinga

    Biotech analysts at Piper Jaffray stated in a note on Wednesday that "we are buyers on weakness" of select biotech names that boast strong enough balance sheets to "make it through" upcoming value-driving events. The analysts, led by Edward Tenthoff, singled out Vertex Pharmaceuticals Incorporated , Novavax, Inc. , Alnylam Pharmaceuticals, Inc. along with Arrowhead Research Corp being a smaller cap name.

    Comment?

  7. Here's who Mass. biotechs are supporting in recent electionsRead the original story w/Photo

    Wednesday Aug 26 | Business Journal

    ... at the campaign contributions since 2014 for three of the state's largest biotech firms: Biogen (Nasdaq: BIIB) and Vertex Pharmaceuticals (Nasdaq: VRTX), which are both based here, and EMD Serono , the U.S. pharmaceutical division of German-based ...

    Comment?

  8. Vertex Pharmaceuticals Raised to "Buy" at Vetr Inc.Read the original story

    Saturday Aug 22 | AmericanBankingNews.com

    ... stock. Vetr 's price objective would indicate a potential upside of 13.63% from the company's current price. Vertex Pharmaceuticals ( NASDAQ:VRTX ) traded down 5.60% on Monday, reaching $125.47. 2,505,007 shares of the company's stock were ...

    Comment?

  9. Vertex Pharmaceuticals Director Sells $1,455,272.00 in StockRead the original story

    Thursday Aug 20 | AmericanBankingNews.com

    Vertex Pharmaceuticals Director Joshua S. Boger sold 10,400 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $139.93, for a total transaction of $1,455,272.00.

    Comment?

  10. Is it a bank or restaurant? Leader Bank's new Seaport branch boasts comfy seats, barstoolsRead the original story w/Photo

    Tuesday Aug 18 | Business Journal

    ... the Seaport - and it resembles a restaurant. The 2,700-square-foot branch is located on the ground floor of the Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) at 50 Northern Ave. The space is designed to foster a sense of hospitality for the bank's ...

    Comment?

  11. BBJ Live: What you may have missed in recent Bay State biotech newsRead the original story w/Photo

    Tuesday Aug 18 | Business Journal

    Boston Business Journal BioFlash Editor Don Seiffert recently spoke with NECN's Mike Nikitas about recent news in the biotech sector around Boston. Discussion included a drug launch and flap over CEO compensation at Vertex Pharmaceuticals, a promising Alzheimer's drug at Biogen and a drug for Duchenne muscular dystrophy by Sarepta Therapeutics that could be approved earl next year.

    Comment?

  12. Vertex Pharmaceuticals (VRTX) - Investment Analysts' Weekly Ratings UpdatesRead the original story

    Tuesday Aug 18 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of Vertex Pharmaceuticals in the last few weeks: 8/17/2015 - Vertex Pharmaceuticals was upgraded by analysts at Vetr from a "hold" rating to a "buy" rating. They now have a $142.57 price target on the stock.

    Comment?

  13. In the shadow of Vertex, small cystic fibrosis-focused biotechs thriveRead the original story w/Photo

    Monday Aug 17 | Business Journal

    The undisputed leader in the field of drugs to treat cystic fibrosis is Boston's Vertex Pharmaceuticals , but that company's success is spurring some smaller, recently-public biotechs to focus on drugs to treat the inherited, fatal disease. Corbus Pharmaceuticals in Norwood, which just started trading on the Nasdaq exchange in April, has attracted attention for its potential drug , Resunab, which is about to begin mid-stage trials to treat inflammation associated with CF.

    Comment?

  14. Vertex Pharmaceuticals Director Sells $1,412,632.00 in StockRead the original story

    Monday Aug 17 | AmericanBankingNews.com

    Vertex Pharmaceuticals Director Joshua S. Boger sold 10,400 shares of the firm's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $135.83, for a total transaction of $1,412,632.00.

    Comment?

  15. Vertex Pharmaceuticals A Solid Bet Past Q3Read the original story w/Photo

    Friday Aug 14 | Seeking Alpha

    Given that ORKAMBI will eventually become wildly successful, the market could be forgiving of a miss, and eventually rewarding for holders. Vertex Pharmaceuticals is a large biotechnology company focused on the hereditary disorder cystic fibrosis , which affects approximately 70,000 and 100,000 people worldwide .

    Comment?

  16. Boston cuts Vertex Pharmaceuticals tax break by $3MRead the original story

    Wednesday Aug 12 | WLNE-TV Providence

    Boston has reduced the tax break it agreed to give Vertex Pharmaceuticals Inc. for moving to the city by $3 million for failing to create as many new jobs as anticipated. The city said Tuesday the tax incentives had been cut by 25 percent from about $12 million to $9 million through the 2018 fiscal year.

    Comment?

  17. a Five things you need to know today, and why old folks should love BostonRead the original story w/Photo

    Wednesday Aug 12 | Business Journal

    ... Boston! Here are the five most important things you need to know to help start your busy business day. Why Vertex fell short on its job-creation vows to the city In May 2011, just days after the FDA approval of the first-ever drug by Vertex ...

    Comment?

  18. Why Vertex Fell Short on Its Job Creation Promise to CambridgeRead the original story

    Tuesday Aug 11 | BioSpace

    In May 2011, just days after the FDA approval of the first-ever drug by Vertex Pharmaceuticals, company executives had a lot of reasons to be optimistic. Incivek, approved to treat hepatitis C, had shown it was able to cure 79 percent of patients with the disease in a far-shorter duration than alternative drugs.

    Comment?

  19. Vertex Pharmaceuticals Upgraded to Buy at Vetr Inc.Read the original story

    Tuesday Aug 11 | AmericanBankingNews.com

    ... stock's current price. Several other equities analysts also recently commented on the company. Zacks cut shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, August 4th. Deutsche Bank reaffirmed a "buy" ...

    Comment?

  20. a Here's why Vertex fell short on its job-creation vows to the cityRead the original story w/Photo

    Tuesday Aug 11 | Business Journal

    In May 2011, just days after the FDA approval of the first-ever drug by Vertex Pharmaceuticals , company executives had a lot of reasons to be optimistic. Incivek, approved to treat hepatitis C, had shown it was able to cure 79 percent of patients with the disease in a far-shorter duration than alternative drugs.

    Comment?